Publications

Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, CannistraSA.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.  J Clin Oncol. 2010;28(22):3555-3561.

Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan BY, McLaughlin J, Narod SA. Hereditary ovarian cancer clinical study group: risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Gynecol Oncol. 2010;118(2):155-159.

Ibrahim N, He L, Leong CO, Xing D, Karlan BY, Swisher EM, Rueda BR, Orsulic S, Ellisen LW. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res. 2010;70(18):7155-7165.

Bolton KL, Tyrer J, Honglin S, Ramus SJ, Notariou M, Jones C, Sher TM, Gentry-Majaraj A, Wozniak E, Tsai YY, . . . Karlan BY, et al. Common variants at 19p13are associated with susceptibility to ovarian cancerNature Genet. 2010;42(10):880-884.

Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PDP, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ,. . . Karlan BY, et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2011;103(2):105-116.

Fleming N, Cass I, Walsh C, Karlan B, Li A. Early detection of recurrence through CA125 surveillance in women with epithelial ovarian cancer correlates with increased optimal secondary cytoreductive surgery. Gynecol Oncol. 2011;121(2):249-252.

Norquist B, Wurz K, Pennil C, Garcia R, Gross J, Sakai W, Karlan B, Taniguchi T, Swisher E. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29(22):3008-3015.

Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver HA, Antonenkova N, Antoniou AC, . . . Karlan BY, et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res.2011;17(11):3742-3750.

Zajchowski DA, Karlan BY, Shawver LK. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther.2012;11(2):492;501.

Bolton KL, Chenevix-Trench G, Goh C, Siegal S, Ramus SJ, Karlan BY, Lambrechts D, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382-390.

Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Baker SF, Gross J, Kuo W-L, Karlan BY, RuedaBR, Orsulic S, Birrer MJ, Gray JW, Mohapatra G. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLOS ONE. 2012;7(2):e30996.

Ramus S, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM. . . Karlan BY, et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Human Mutation. 2012 Jan 17.

Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, et al.  Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.  J Clin Oncol. 2012;30(4): 362-71.